{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:19:25Z","timestamp":1748963965356},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,9]]},"DOI":"10.7759\/cureus.37335","type":"journal-article","created":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T18:56:01Z","timestamp":1681066561000},"source":"Crossref","is-referenced-by-count":3,"title":["Sacubitril\/Valsartan in Heart Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away?"],"prefix":"10.7759","author":[{"given":"Navya","family":"Sakhamuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekartthik","family":"Athiyaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhawna","family":"Randhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxiong","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maheen F","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maithily","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi Malvika","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie A","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029149","article-title":"Sacubitril\/Valsartan for heart failure: a protocol for systematic review and meta-analysis","volume":"101","author":"Dai W","year":"2022","unstructured":"Dai W, Luo J, Huang X. Sacubitril\/Valsartan for heart failure: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2022, 101:e29149. 10.1097\/MD.0000000000029149","journal-title":"Medicine (Baltimore)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028231","article-title":"Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: a PRISMA-compliant article","volume":"100","author":"Lin J","year":"2021","unstructured":"Lin J, Zhou J, Xie G, Liu J. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: a PRISMA-compliant article. Medicine (Baltimore). 2021, 100:e28231. 10.1097\/MD.0000000000028231","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10115-8","article-title":"Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper","volume":"27","author":"Ntalianis A","year":"2022","unstructured":"Ntalianis A, Chrysohoou C, Giannakoulas G, et al.. Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Fail Rev. 2022, 27:1-13. 10.1007\/s10741-021-10115-8","journal-title":"Heart Fail Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-157","article-title":"The effect of sacubitril\/valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction","volume":"10","author":"Chen F","year":"2021","unstructured":"Chen F, Tian G, Bai X, Li J, Yuan Z. The effect of sacubitril\/valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction. Ann Palliat Med. 2021, 10:8684-91. 10.21037\/apm-21-157","journal-title":"Ann Palliat Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-21-355","article-title":"Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment","volume":"11","author":"Gu W","year":"2021","unstructured":"Gu W, Xu C, Li Z, Li ZZ. Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment. Cardiovasc Diagn Ther. 2021, 11:1093-100. 10.21037\/cdt-21-355","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11072020","article-title":"An up-to-date article regarding particularities of drug treatment in patients with chronic heart failure","volume":"11","author":"Buda V","year":"2022","unstructured":"Buda V, Prelipcean A, Cozma D, et al.. An up-to-date article regarding particularities of drug treatment in patients with chronic heart failure. J Clin Med. 2022, 11:2020. 10.3390\/jcm11072020","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23847","article-title":"Insights into foundational therapies for heart failure with reduced ejection fraction","volume":"45 Suppl 1","author":"McMurray JJ","year":"2022","unstructured":"McMurray JJ, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. Clin Cardiol. 2022, 45 Suppl 1:S26-30. 10.1002\/clc.23847","journal-title":"Clin Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10137-2","article-title":"Current and emerging drug targets in heart failure treatment","volume":"27","author":"Ghionzoli N","year":"2022","unstructured":"Ghionzoli N, Gentile F, Del Franco AM, et al.. Current and emerging drug targets in heart failure treatment. Heart Fail Rev. 2022, 27:1119-36. 10.1007\/s10741-021-10137-2","journal-title":"Heart Fail Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2259","article-title":"Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial","volume":"23","author":"Bhatt AS","year":"2021","unstructured":"Bhatt AS, Vaduganathan M, Claggett BL, et al.. Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021, 23:1518-24. 10.1002\/ejhf.2259","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.08.003","article-title":"Comparative effectiveness of sacubitril-valsartan\u00a0versus ACE\/ARB therapy in heart failure with reduced\u00a0ejection fraction","volume":"8","author":"Tan NY","year":"2020","unstructured":"Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM. Comparative effectiveness of sacubitril-valsartan\u00a0versus ACE\/ARB therapy in heart failure with reduced\u00a0ejection fraction. JACC Heart Fail. 2020, 8:43-54. 10.1016\/j.jchf.2019.08.003","journal-title":"JACC Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88791","article-title":"Variation in early diffusion of sacubitril\/valsartan and implications for understanding novel drug diffusion","volume":"27","author":"Gilstrap L","year":"2021","unstructured":"Gilstrap L, King A, Tomlin S, Austin AM. Variation in early diffusion of sacubitril\/valsartan and implications for understanding novel drug diffusion. Am J Manag Care. 2021, 27:524-30. 10.37765\/ajmc.2021.88791","journal-title":"Am J Manag Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23717","article-title":"Efficacy and safety of early initiation of sacubitril\/valsartan in patients after acute myocardial infarction: a meta-analysis","volume":"44","author":"Zhao J","year":"2021","unstructured":"Zhao J, Zeng Y, Shen X. Efficacy and safety of early initiation of sacubitril\/valsartan in patients after acute myocardial infarction: a meta-analysis. Clin Cardiol. 2021, 44:1354-9. 10.1002\/clc.23717","journal-title":"Clin Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10120-x","article-title":"Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations from new promising clinical trials","volume":"27","author":"D\u0119bska-Koz\u0142owska A","year":"2022","unstructured":"D\u0119bska-Koz\u0142owska A, Ksi\u0105\u017cczyk M, Lelonek M. Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations from new promising clinical trials. Heart Fail Rev. 2022, 27:419-30. 10.1007\/s10741-021-10120-x","journal-title":"Heart Fail Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.04.006","article-title":"Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril\/valsartan. Position Paper of the Italian Society of Cardiology","volume":"102","author":"Perrone-Filardi P","year":"2022","unstructured":"Perrone-Filardi P, Paolillo S, Agostoni P, et al.. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril\/valsartan. Position Paper of the Italian Society of Cardiology. Eur J Intern Med. 2022, 102:8-16. 10.1016\/j.ejim.2022.04.006","journal-title":"Eur J Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-021-00252-4","article-title":"Hospitalization rates in patients with heart failure and reduced ejection fraction initiating sacubitril\/valsartan or angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers: a retrospective cohort study","volume":"11","author":"Houchen E","year":"2022","unstructured":"Houchen E, Loefroth E, Schlienger R, et al.. Hospitalization rates in patients with heart failure and reduced ejection fraction initiating sacubitril\/valsartan or angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers: a retrospective cohort study. Cardiol Ther. 2022, 11:113-27. 10.1007\/s40119-021-00252-4","journal-title":"Cardiol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review","volume":"8","author":"Pascual-Figal D","year":"2021","unstructured":"Pascual-Figal D, Bay\u00e9s-Genis A, Beltr\u00e1n-Troncoso P, et al.. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review. Front Cardiovasc Med. 2021, 8:754499. 10.3389\/fcvm.2021.754499","journal-title":"Front Cardiovasc Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v13.i8.325","article-title":"Angiotensin receptor blocker neprilysin inhibitors","volume":"13","author":"Usuda D","year":"2021","unstructured":"Usuda D, Higashikawa T, Hotchi Y, et al.. Angiotensin receptor blocker neprilysin inhibitors. World J Cardiol. 2021, 13:325-39. 10.4330\/wjc.v13.i8.325","journal-title":"World J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13624","article-title":"Recent advances in pharmacological treatment of heart failure","volume":"51","author":"Iacoviello M","year":"2021","unstructured":"Iacoviello M, Palazzuoli A, Gronda E. Recent advances in pharmacological treatment of heart failure. Eur J Clin Invest. 2021, 51:e13624. 10.1111\/eci.13624","journal-title":"Eur J Clin Invest"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.844","article-title":"Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: a systematic review and meta-analysis","volume":"9","author":"Charuel E","year":"2021","unstructured":"Charuel E, Menini T, Bedhomme S, et al.. Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: a systematic review and meta-analysis. Pharmacol Res Perspect. 2021, 9:e00844. 10.1002\/prp2.844","journal-title":"Pharmacol Res Perspect"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23744","article-title":"Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: the PERI-STEMI study","volume":"44","author":"Diao K","year":"2021","unstructured":"Diao K, Wang D, Chen Z, et al.. Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: the PERI-STEMI study. Clin Cardiol. 2021, 44:1709-17. 10.1002\/clc.23744","journal-title":"Clin Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221107799","article-title":"Duration of heart failure with reduced ejection fraction associated with electrocardiographic outcomes before and after sacubitril\/valsartan","volume":"27","author":"Lin PL","year":"2022","unstructured":"Lin PL, Lee YH, Liu LY, et al.. Duration of heart failure with reduced ejection fraction associated with electrocardiographic outcomes before and after sacubitril\/valsartan. J Cardiovasc Pharmacol Ther. 2022, 27:10742484221107799. 10.1177\/10742484221107799","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure","volume":"6","author":"Tomasoni D","year":"2019","unstructured":"Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail. 2019, 6:1105-27. 10.1002\/ehf2.12555","journal-title":"ESC Heart Fail"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13547","article-title":"Sacubitril\/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis","volume":"8","author":"Giovinazzo S","year":"2021","unstructured":"Giovinazzo S, Carmisciano L, Toma M, et al.. Sacubitril\/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021, 8:3547-56. 10.1002\/ehf2.13547","journal-title":"ESC Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.602363","article-title":"Hospitalization and mortality in patients with heart failure treated with sacubitril\/valsartan vs. enalapril: a real-world, population-based study","volume":"7","author":"Pathadka S","year":"2020","unstructured":"Pathadka S, Yan VK, Li X, et al.. Hospitalization and mortality in patients with heart failure treated with sacubitril\/valsartan vs. enalapril: a real-world, population-based study. Front Cardiovasc Med. 2020, 7:602363. 10.3389\/fcvm.2020.602363","journal-title":"Front Cardiovasc Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263131","article-title":"Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Liu X","year":"2022","unstructured":"Liu X, Liu H, Wang L, Zhang L, Xu Q. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2022, 17:e0263131. 10.1371\/journal.pone.0263131","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029456","article-title":"A narrative review on sacubitril\/valsartan and ventricular arrhythmias","volume":"101","author":"Wei Z","year":"2022","unstructured":"Wei Z, Zhang M, Zhang Q, et al.. A narrative review on sacubitril\/valsartan and ventricular arrhythmias. Medicine (Baltimore). 2022, 101:e29456. 10.1097\/MD.0000000000029456","journal-title":"Medicine (Baltimore)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.890481","article-title":"Effect of sacubitril\/valsartan on reducing the risk of arrhythmia: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Wang R","year":"2022","unstructured":"Wang R, Ye H, Ma L, Wei J, Wang Y, Zhang X, Wang L. Effect of sacubitril\/valsartan on reducing the risk of arrhythmia: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2022, 9:890481. 10.3389\/fcvm.2022.890481","journal-title":"Front Cardiovasc Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-210","article-title":"Therapeutic effects and safety of early use of sacubitril\/valsartan after acute myocardial infarction: a systematic review and meta-analysis","volume":"11","author":"Zhang L","year":"2022","unstructured":"Zhang L, Yan K, Zhao H, Shou Y, Chen T, Chen J. Therapeutic effects and safety of early use of sacubitril\/valsartan after acute myocardial infarction: a systematic review and meta-analysis. Ann Palliat Med. 2022, 11:1017-27. 10.21037\/apm-22-210","journal-title":"Ann Palliat Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13677","article-title":"The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis","volume":"8","author":"Xiong B","year":"2021","unstructured":"Xiong B, Nie D, Qian J, et al.. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail. 2021, 8:4852-62. 10.1002\/ehf2.13677","journal-title":"ESC Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart\u00a0failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan M","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Desai AS, et al.. Prior heart\u00a0failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol. 2020, 75:245-54. 10.1016\/j.jacc.2019.11.003","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01079-6","article-title":"Cost-utility analysis of sacubitril-valsartan compared with enalapril treatment in patients with acute decompensated heart failure in Thailand","volume":"41","author":"Krittayaphong R","year":"2021","unstructured":"Krittayaphong R, Permsuwan U. Cost-utility analysis of sacubitril-valsartan compared with enalapril treatment in patients with acute decompensated heart failure in Thailand. Clin Drug Investig. 2021, 41:907-15. 10.1007\/s40261-021-01079-6","journal-title":"Clin Drug Investig"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026809","article-title":"Clinical characteristics, prescription patterns, and persistence associated with sacubitril\/valsartan adoption: a STROBE-compliant study","volume":"100","author":"Chen W","year":"2021","unstructured":"Chen W, Liu Y, Tang L, Li Z, Liu Y, Dang H. Clinical characteristics, prescription patterns, and persistence associated with sacubitril\/valsartan adoption: a STROBE-compliant study. Medicine (Baltimore). 2021, 100:e26809. 10.1097\/MD.0000000000026809","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/112651-sacubitrilvalsartan-in-heart-failure-hospitalization-two-pills-a-day-to-keep-hospitalizations-away","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:50:02Z","timestamp":1707508202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/112651-sacubitrilvalsartan-in-heart-failure-hospitalization-two-pills-a-day-to-keep-hospitalizations-away"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,9]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.37335","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,9]]}}}